Combinatorial drug delivery approaches for immunomodulation
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Immunotherapy has been widely explored for applications to both augment and suppress intrinsic host immunity. Clinical achievements have seen a number of immunotherapeutic drugs displace established strategies like chemotherapy in treating immune‐associated diseases. However, single drug approaches modulating an individual arm of the immune system are often incompletely effective. Imperfect mechanistic understanding and heterogeneity within disease pathology have seen monotherapies inadequately equipped to mediate complete disease remission. Recent success in applications of combinatorial immunotherapy has suggested that targeting multiple biological pathways simultaneously may be critical in treating complex immune pathologies. Drug delivery approaches through engineered biomaterials offer the potential to augment desired immune responses while mitigating toxic side‐effects by localizing immunotherapy. This review discusses recent advances in immunotherapy and highlights newly explored combinatorial drug delivery approaches. Furthermore, prospective future directions for immunomodulatory drug delivery to exploit are provided. Graphical abstract Figure. No Caption available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · cited 1×
“Checkpoint blockade therapy has buoyed the enthusiasm for monoclonal antibody immunotherapy, as it has produced some of the most successful human clinical trials for cancer in recent years (reviewed in [115]).”
Polymeric systems for controlled drug release
Uhrich, K. E., Cannizzaro, S. M., Langer, R. S., & Shakesheff, K. M. (1999) · Chemical Reviews · doi:10.1021/cr940351u · Cited by 2,633 · cited 1×
“Particle-based approaches are valuable for drug delivery because they are often highly tunable, provide a sustained release depot for encapsulated agents, reduce systemic toxicity and dosing requirements, and simplifymanufacturing, storage and shipping concerns [43,44].”
He, C., Hu, Y., Yin, L., Tang, C., & Yin, C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.065 · Cited by 2,607
Merad, M., Sathe, P., Helft, J., Miller, J., & Mortha, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-074950 · Cited by 2,309
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., & Levy, R. (1996) · Nature Medicine · doi:10.1038/nm0196-52 · Cited by 1,804 · cited 1×
“Since the first clinical trial using DC-based vaccination in 1996 [30], numerous studies have demonstrated induction of antigen-specific T and B cell responses against malignant cancers using DCs primed with tumor-associated antigens [31,32].”
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688 · cited 1×
“Like DC-based therapies, various strategies to modulate T cell numbers and activity ex-vivo for adoptive transfer therapyhave been investigated (reviewed in [70]).”
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944 · cited 1×
“In cancer immunotherapy alone, there are over 50 immunotherapy agents currently being used in the clinic or in clinical trials [4].”
Regulation of Dendritic Cell Migration to the Draining Lymph Node
Martín-Fontecha, A., Sebastiani, S., Höpken, U. E., Uguccioni, M., Lipp, M., Lanzavecchia, A., & Sallusto, F. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030448 · Cited by 878 · cited 1×
“While DC-based immunotherapy has demonstrated clinical efficacy, administration of exogenously-treated DCs exhibits numerous barriers for widespread implementation including high cost, poor yield, and inefficient DC homing to regional lymph nodes [40,41].”
Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance
Maldonado, R. A., LaMothe, R. A., Ferrari, J. D., Zhang, A.-H., Rossi, R. J., Kolte, P. N., Griset, A. P., O’Neil, C., Altreuter, D. H., Browning, E., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408686111 · Cited by 441
Therapeutic Inflammatory Monocyte Modulation Using Immune-Modifying Microparticles
Getts, D. R., Terry, R. L., Getts, M. T., Deffrasnes, C., Müller, M., van Vreden, C., Ashhurst, T. M., Chami, B., McCarthy, D., Wu, H., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007563 · Cited by 378
Cited by
Zhou, W., Zhou, Y., Chen, X., Ning, T., Chen, H., Guo, Q., Zhang, Y., Liu, P., Zhang, Y., Li, C., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120546 · Cited by 425
Circular RNA vaccine in disease prevention and treatment
Niu, D., Wu, Y., & Lian, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01561-x · Cited by 267
Control of innate immune response by biomaterial surface topography, energy, and stiffness
Abaricia, J. O., Farzad, N., Heath, T. J., Simmons, J., Morandini, L., & Olivares-Navarrete, R. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.04.021 · Cited by 199
Sadowska, J. M., & Ginebra, M.-P. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb01379j · Cited by 144
Metadata
- Authors
- Stewart, J. M., & Keselowsky, B. G.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 114
- Pages
- 161-174
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2614623561
- Cited by
- 53
- References
- 13
- FWCI
- 0.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combinatorial drug delivery approaches for immunomodulation. https://app.cochat.ai/papers/10.1016/j.addr.2017.05.013
- The paper
- Stewart, J. M., & Keselowsky, B. G. (2017). Combinatorial drug delivery approaches for immunomodulation. Advanced Drug Delivery Reviews. https://doi.org/10.1016/j.addr.2017.05.013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.